31 results about "Nocturnal polyuria" patented technology

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

A method for preventive and / or therapeutic treatment of nocturia, which comprises the step of administering to a mammal including a human in need of such treatment a preventively and / or therapeutically effective amount of a nonsteroidal anti-inflammatory drug such as loxoprofen.

The present invention relates to phenyl or heteroaryl amino alkane derivatives of formula (I) in which the groups Q1-Q4, Ar, and R1-R7 are as defined in the specification and claims. These materials are useful as active ingredients of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorders as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since these diseases also are alleviated by treatment with an IP receptor antagonist. The application claims the compounds, pharmaceutical compositions containing them, and methods of treatment using them.

A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and / or diabetes insipidus, is provided.

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

The invention relates to methods of treating or slowing the onset of overactive bladder or urinary incontinence, or a symptom thereof selected from urinary frequency, urinary urgency, nocturia, or enuresis comprising identifying and administering to a subject in need of treatment a therapeutically effective amount of a compound according to Formulae I-V, as defined herein.

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.

Disclosed is a pharmaceutical formulation that may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.

The invention relates to an oral Yiniao Kangfu capsule prepared by taking Chinese herbal medicines as raw materials and used for curing nocturia. Taking eight Chinese herbal medicines, such as codonopsis pilosula, astragalus roots, fructus alpiniae oxyphyllae, tenodera aridifolia stoll, Chinese dodder seeds, red raspberries, cherokee roses and malaytea scurfpea, as the raw materials, the capsule is obtained by nine processing steps, such as material selecting, cleaning, drying, grinding, sieving, mixing, capsule filling, split charging and packing. According to the clinical observation, the oral Yiniao Kangfu capsule has the advantages of good and fast curative effect and high curative ratio for curing nocturia, simple manufacture, convenient taking, low cost, and the like.

The invention discloses a diaphragmajuglandisfructus health-preserving solid tea and a preparation method thereof. The diaphragmajuglandisfructus health-preserving solid tea is prepared from, by mass,30-40 parts of red dates, 10-20 parts of medlar, 10-20 parts of walnut, 10-20 parts of diaphragmajuglandisfructus, 1-10 parts of mulberry, 1-10 parts of liquorice and 1-5 parts of purified water. Thediaphragmajuglandisfructus health-preserving solid tea has the advantages that the diaphragmajuglandisfructus health-preserving solid tea has a strong health-care function after being soaked with water, has a good curative effect on treating insomnia, can also play a certain role in nourishing the kidney and arresting seminal emission when being taken by men, and can relieve male sexual dysfunction; if women have cold hands and feet, walnut diaphragmajuglandisfructus health-preserving solid tea also has a good effect after being soaked with water; and if old people have waist soreness and back pain when seasons change, the diaphragmajuglandisfructus health-preserving solid tea can also be taken frequently. The walnut diaphragmajuglandisfructus kidney-tonifying essence-generating health tea produced by the invention can be used for clinical verification of dizziness, tiredness, waist soreness, leg pain and excessive nocturia caused by kidney deficiency and aging, has obvious effect, has no toxic or side effect, and is suitable for a wide range of people.

The present invention relates to carboxamides which are useful as an active ingredient of pharmaceutical preparations. The carboxamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the diseases are alleviated by treatment with an IP receptor antagonist.

The invention discloses traditional Chinese medicine capsules for treating nocturia. The capsules are prepared from traditional Chinese medicinal materials in parts by weight as follows: 10 parts of Chinese yams, 7 parts of prepared rehmannia roots, 4 parts of oriental waterplantain rhizomes, 5 parts of tree peony bark, 1.5 parts of cassia bark, 6 parts of all-grass of bulley herminium, 9 parts of prepared common monkshood daughter roots, 6 parts of palmleaf raspberry fruits, 5 parts of semiaquilegia seeds, 4 parts of Borassus flabellifer, 3 parts of rhubarb, 6 parts of smallage seeds, 3 parts of Commiphora mukul, 4 parts of willow leaves, 6 parts of piptostegia roots and 9 parts of semen lepidii. Clinical experiments prove that through selection of the proper medicinal materials and ratio of the medicinal materials, the capsules have the significant effect of treating the nocturia and are safe and free of toxic and side effects.

The invention discloses a Zhuang pharmaceutical composition for treating oligospermia. The Zhuang pharmaceutical composition is prepared from the following raw materials in parts by weight: 10-50 parts of beautiful millettia root, 10-40 parts of cherokee rose fruit, 10-30 parts of cuscuta, 10-30 parts of ventilago leiocarpa benth, 10-30 parts of root of false-yellowflower milkwort, 5-25 parts of semen plantaginis and 5-25 parts of common rush. A preparation method of the Zhuang pharmaceutical composition comprises the following steps: respectively weighing the raw materials in parts by weight, cleaning the raw materials, mixing, and soaking the raw materials for 0.5-1h in water; decocting for the first time: decocting the mixture with strong fire until a medical solution is boiled, decocting for 20-25 minutes with gentle fire, and filtering out medicine juice; decocting for the second time: adding constant-temperature water until the water level is higher than the plane of the medicinal materials by 0.5-1cm, decocting with strong fire until the medical solution is boiled, decocting for 15-20 minutes with gentle fire, and filtering out medicine juice; and mixing the medicine juice prepared by the decoction for the first time and the decoction for the second time to prepare the Zhuang pharmaceutical composition. The Zhuang pharmaceutical composition has the efficacies of tonifying deficiency, boosting essence, regulating qi, dispelling dampness and dredging channels, is obvious in sperm producing effect and is capable of improving symptoms of soreness and weakness of waist and knees, intolerance of cold, preference in warmth and increase of nocturia.

There is provided a pharmaceutical composition which includes, as an active ingredient, a combination drug formulation of potassium citrate and sodium citrate hydrate or a sodium bicarbonate formulation. The prevention or treatment of nocturnal polyuria is achieved by administering the pharmaceutical composition.

A method for therapeutic treatment of nocturia which comprises administering to a mammal, including a human in need of such treatment, a therapeutically effective amount of loxoprofen or a pharmacologically acceptable salt thereof.

The invention discloses a Chinese herbal decoction for treating nocturnal polyuria. The Chinese herbal decoction is prepared from the following traditional Chinese medicinal materials by weight: 7 parts of the root and rhizome of Sphallerocarpus gracilis, 7 parts of the whole herb of Herminium coiloglossum, 7 parts of melon seeds, 7 parts of the leaf of Cassia siamea, 6 parts of common alstonia leaves, 12 parts of Radix Bupleuri, 8 parts of cherokee rose-hip, 14 parts of Fructus Rhois coriariae, 9 parts of the root or whole herb of Sedum aizoon L., 6 parts of the whole herb of Duchesnea indica, 8 parts of Rhizoma Atractylodis, 6 parts of polygala roots, 6 parts of grass-leaved sweetflag rhizomes, 6 parts of bone fossil of big mammals, 6 parts of Oviductus Ranae, 6 parts of dried lotus seeds, 25 parts of Radix Aconiti carmichaeli, 5 parts of Piper flaviflorum, 6 parts of vinegar-processed tortoiseshells, 5 parts of the seed of welsh-onion, 12 parts of Rhodobryum giganteum, 10 parts of the whole herb of Chimaphila umbellate, 5 parts of oriental waterplantain rhizomes, 5 parts of the overground part of Monochoria korsakowii, 5 parts of the root of Helicteres elongate, 5 parts of the frond of Ceramium kondoi Yendo and Ceramium boydenii Gepp, 6 parts of the tassel of Zea mays and 6 parts of marshy betony herb. Clinical experiments prove that through reasonable combination of the Daidrug the leaf of Cassia siamea and other traditional Chinese medicinal materials, the prepared Chinese herbal decoction is beneficial for treatment of nocturnal polyuria, can effectively reduce complications of nocturnal polyuria and achieves good integral adjusting and long-term treatment effects.

The invention discloses a preparation method of an umbilical sticking agent for treating nocturia of children, so as to solve the problem of treatment of the nocturia of children. The preparation method is characterized by comprising the following steps of (1) distilling bark of himalayan coralbean, immature bitter orange and radix ephedrae crude product at reduced pressure, and extracting essential oil; (2) decocting the bobbin at reduced pressure to obtain filtrate; (3) decocting smallflower bracketplant herb, alpinia japonica, jasminum grandiflorum, dark malt, burnt medicated leaven, manis pentadactyla, peach gum rhizome anemones altaicae and drug residue obtained in the step (1) to obtain filtrate for future use; (4) merging the filtrate obtained in the steps 2 and 3; concentrating at reduced pressure into dry extract, and crushing to obtain the dry extract powder; and (5) spraying the essential oil obtained in the step (1) to the dry extract powder obtained in the step 4; performing uniform mixing, filtering by a 100-mesh sieve, and sub-charging. The clinical test shows that the drug for treating the nocturia of children has the characteristics of good curative effect and high safety on treatment of the nocturia of children, and is worthy of clinical application and popularization.

The invention discloses a Chinese herbal capsule for treating nocturnal polyuria. The Chinese herbal capsule is prepared from the following traditional Chinese medicinal materials by weight: 7 parts of the root and rhizome of Sphallerocarpus gracilis, 7 parts of the whole herb of Herminium coiloglossum, 7 parts of melon seeds, 7 parts of the leaf of Cassia siamea, 6 parts of common alstonia leaves, 12 parts of Radix Bupleuri, 8 parts of cherokee rose-hip, 14 parts of Fructus Rhois coriariae, 9 parts of the root or whole herb of Sedum aizoon L., 6 parts of the whole herb of Duchesnea indica, 8parts of Rhizoma Atractylodis, 6 parts of polygala roots, 6 parts of grass-leaved sweetflag rhizomes, 6 parts of bone fossil of big mammals, 6 parts of dried ginseng, 6 parts of dried lotus seeds, 25parts of Radix Aconiti carmichaeli, 5 parts of Piper flaviflorum, 6 parts of vinegar-processed tortoiseshells, 5 parts of the seed of welsh-onion, 12 parts of Rhodobryum giganteum, 10 parts of the whole herb of Chimaphila umbellate, 5 parts of oriental waterplantain rhizomes, 5 parts of the overground part of Monochoria korsakowii, 5 parts of the root of Helicteres elongate, 5 parts of the frond of Ceramium kondoi Yendo and Ceramium boydenii Gepp, 6 parts of the tassel of Zea mays and 6 parts of marshy betony herb. Clinical experiments prove that through reasonable combination of the Dai drugthe leaf of Cassia siamea and other traditional Chinese medicinal materials, the prepared Chinese herbal capsule is beneficial for treatment of nocturnal polyuria, can effectively reduce complicationsof nocturnal polyuria and achieves good integral adjusting and long-term treatment effects.

The invention provides a traditional Chinese medicine for treating nocturnal polyuria in the elderly. The traditional Chinese medicine comprises, by weight, 13-17 parts of leaves of Cassia siamea Lam., 6-8 parts of dandelion, 8-12 parts of wild mountain sesame seeds, 5-7 parts of bighead atractylodes rhizome, 8-10 parts of rhizoma acori graminei, 7-13 parts of common alstonia leaf, 6-8 parts of rhodobryum giganteum, 3-5 parts of Sphallerocarpus gracilis, 4-6 parts of Hermini-um balleyi, 9-11 parts of Patrinia scabiosaefolia Fisch, 1-5 parts of unprocessed rehmannia root, 10-14 parts of processed ginger, 12-16 parts of rhizoma rehmanniae, 7-9 parts of muskmelon seed, 10-12 parts of radix caulophylli, 12-20 parts of lotus seed, 8-12 parts of red peony root, 12-16 parts of felwort and 9-13 parts of root bark of the peony tree. The traditional Chinese medicine has the advantages of remarkable curative effect, simple medicine properties, simple use method, convenient taking, treatment on nocturnal polyuria in the elderly and reduction of complications and achieves good effects of overall regulation and long-term action.

The invention discloses a Zhuang pharmaceutical composition for treating oligospermia. The Zhuang pharmaceutical composition is prepared from the following raw materials in parts by weight: 10-50 parts of beautiful millettia root, 10-40 parts of cherokee rose fruit, 10-30 parts of cuscuta, 10-30 parts of ventilago leiocarpa benth, 10-30 parts of root of false-yellowflower milkwort, 5-25 parts of semen plantaginis and 5-25 parts of common rush. A preparation method of the Zhuang pharmaceutical composition comprises the following steps: respectively weighing the raw materials in parts by weight, cleaning the raw materials, mixing, and soaking the raw materials for 0.5-1h in water; decocting for the first time: decocting the mixture with strong fire until a medical solution is boiled, decocting for 20-25 minutes with gentle fire, and filtering out medicine juice; decocting for the second time: adding constant-temperature water until the water level is higher than the plane of the medicinal materials by 0.5-1cm, decocting with strong fire until the medical solution is boiled, decocting for 15-20 minutes with gentle fire, and filtering out medicine juice; and mixing the medicine juice prepared by the decoction for the first time and the decoction for the second time to prepare the Zhuang pharmaceutical composition. The Zhuang pharmaceutical composition has the efficacies of tonifying deficiency, boosting essence, regulating qi, dispelling dampness and dredging channels, is obvious in sperm producing effect and is capable of improving symptoms of soreness and weakness of waist and knees, intolerance of cold, preference in warmth and increase of nocturia.

The present invention provides compounds of general formula: (I) wherein Y is a moiety selected independently, from NH OR -(CH2)- wherein n is 1; m is an integer from 1 to 2; and the moiety (a) represents: (1) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen (wherein A is nitrogen, and B and C are CH), (2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen (wherein A is carbon, B is nitrogen, and C is -CH-CH-), (3) a 6-membered aromatic (unsaturated) ring (wherein A is carbon, B is CH, and C is -CH-CH-); as well as methods and pharmaceutical compositions utilizing these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus noctural enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.

The present invention provides benzoheterocyclic carboxyamides, particularly pyridobenzodiazepine and pyridobenzoxazepine carboxyamides, of general formula (I), wherein: W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilizing these compounds for providing a temporary delay of urination or for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding or coagulation disorders.

The invention discloses a Chinese herbal decoction for treating senile nocturnal polyuria. The Chinese herbal decoction is prepared from the following traditional Chinese medicinal materials by weight: 7 parts of the root and rhizome of Sphallerocarpus gracilis, 7 parts of the whole herb of Herminium coiloglossum, 7 parts of melon seeds, 7 parts of the leaf of Cassia siamea, 6 parts of common alstonia leaves, 12 parts of mantis egg-cases, 8 parts of cherokee rose-hip, 14 parts of Fructus Rhois coriariae, 9 parts of the root or whole herb of Sedum aizoon L., 6 parts of the whole herb of Duchesnea indica, 8 parts of Rhizoma Atractylodis, 6 parts of polygala roots, 6 parts of grass-leaved sweetflag rhizomes, 6 parts of Herba Lysimachiae, 6 parts of dried ginseng, 6 parts of dried lotus seeds,25 parts of Radix Aconiti carmichaeli, 5 parts of the dried whole herb of pyrola, 6 parts of vinegar-processed tortoiseshells, 5 parts of the seed of fistular onion, 12 parts of donkey milk, 10 partsof the whole herb of Chimaphila umbellate, 5 parts of oriental waterplantain rhizomes, 5 parts of the overground part of Monochoria korsakowii, 5 parts of the root of Helicteres elongate, 5 parts oflevant cotton, 6 parts of the tassel of Zea mays and 6 parts of marshy betony herb. Clinical experiments prove that through reasonable combination of the Dai medicine the leaf of Cassia siamea and other traditional Chinese medicinal materials, the prepared Chinese herbal decoction is beneficial for treatment of senile nocturnal polyuria, can effectively reduce recurrence of senile nocturnal polyuria and achieves good integral adjusting and long-term treatment effects.

The invention discloses a preparation method of an umbilical sticking agent for treating nocturia of children, so as to solve the problem of treatment of the nocturia of children. The preparation method is characterized by comprising the following steps of (1) distilling bark of himalayan coralbean, immature bitter orange and radix ephedrae crude product at reduced pressure, and extracting essential oil; (2) decocting the bobbin at reduced pressure to obtain filtrate; (3) decocting smallflower bracketplant herb, alpinia japonica, jasminum grandiflorum, dark malt, burnt medicated leaven, manis pentadactyla, peach gum rhizome anemones altaicae and drug residue obtained in the step (1) to obtain filtrate for future use; (4) merging the filtrate obtained in the steps 2 and 3; concentrating at reduced pressure into dry extract, and crushing to obtain the dry extract powder; and (5) spraying the essential oil obtained in the step (1) to the dry extract powder obtained in the step 4; performing uniform mixing, filtering by a 100-mesh sieve, and sub-charging. The clinical test shows that the drug for treating the nocturia of children has the characteristics of good curative effect and high safety on treatment of the nocturia of children, and is worthy of clinical application and popularization.

The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically an agent for treating nocturia.The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and / or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-(pyridylmethyl)-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia.The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and / or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-(bi-cyclic pyridylmethyl)-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

The invention discloses a Chinese herbal capsule for treating senile nocturnal polyuria. The Chinese herbal capsule is prepared from the following traditional Chinese medicinal materials by weight: 7parts of the root and rhizome of Sphallerocarpus gracilis, 7 parts of the whole herb of Herminium coiloglossum, 7 parts of melon seeds, 7 parts of the leaf of Cassia siamea, 6 parts of common alstonialeaves, 12 parts of mantis egg-cases, 8 parts of cherokee rose-hip, 14 parts of Fructus Rhois coriariae, 9 parts of the root or whole herb of Sedum aizoon L., 6 parts of the whole herb of Duchesnea indica, 8 parts of Rhizoma Atractylodis, 6 parts of polygala roots, 6 parts of grass-leaved sweetflag rhizomes, 6 parts of Herba Lysimachiae, 6 parts of dried ginseng, 6 parts of dried lotus seeds, 25parts of Radix Aconiti carmichaeli, 5 parts of the dried whole herb of pyrola, 6 parts of vinegar-processed tortoiseshells, 5 parts of the seed of welsh-onion, 12 parts of Rhodobryum giganteum, 10 parts of the whole herb of Chimaphila umbellate, 5 parts of oriental waterplantain rhizomes, 5 parts of the overground part of Monochoria korsakowii, 5 parts of the root of Helicteres elongate, 5 parts of levant cotton, 6 parts of the tassel of Zea mays and 6 parts of marshy betony herb. Clinical experiments prove that through reasonable combination of the Dai drug the leaf of Cassia siamea and othertraditional Chinese medicinal materials, the prepared Chinese herbal capsule is beneficial for treatment of senile nocturnal polyuria, can effectively reduce complications of senile nocturnal polyuria and achieves good integral adjusting and long-term treatment effects.

The invention discloses a pharmaceutical composition for treating nocturia of children, so as to solve the problem of treatment of the nocturia of children. The pharmaceutical composition is characterized by being prepared from the following crude drugs: bark of himalayan coralbean, smallflower bracketplant herb, bobbin, alpinia japonica, jasminum grandiflorum, immature bitter orange, dark malt, burnt medicated leaven, Chinese ephedra root, manis pentadactyla, peach gum, and rhizome anemones altaicae. The clinical test shows that the pharmaceutical composition has the characteristics of good curative effect and high safety on treatment of the nocturia of children, and is worthy of clinical application and popularization.